FTSE MIB
30.403,90 +282,13 (+0,94%) Dow Jones
36.247,87 +130,49 (+0,36%) Nasdaq
14.403,97 +63,98 (+0,45%) Nikkei 225
32.307,86 -550,45 (-1,68%) Petrolio
71,26 +1,92 (+2,77%) Bitcoin EUR
40.568,16 -469,11 (-1,14%)
INCY Dec 2023 50.000 call
| Chiusura precedente | 4,7000 |
| Aperto | 5,1700 |
| Denaro | 3,5000 |
| Lettera | 5,0000 |
| Prezzo d'esercizio | 50,00 |
| Scadenza | 2023-12-15 |
| Min-Max giorno | 4,7000 - 5,1700 |
| Contratto - Min-Max | N/D |
| Volume | |
| Open Interest | 21 |
GlobeNewswireGlobal CAR T-cell Therapy Market Projected to Reach $83 Billion by 2032
PALM BEACH, Fla., Oct. 12, 2023 (GLOBE NEWSWIRE) -- FinancialNewsMedia.com News Commentary - Significant influences driving the CAR T-cell therapy market is a rising demand for model therapeutics for treatment of cancer, increase in prevalence of cancer and an escalating awareness of CAR T-cell therapy medicines. The CAR T-cell therapy market is currently going through a rapid expansion, owing to rapidly expanding clinical trial activities and recent commercialization of CAR-T cell therapy, whic
GlobeNewswireKnight Therapeutics Announces Regulatory Submission of Pemigatinib in Brazil
MONTREAL, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Brazilian affiliate, United Medical Ltd., has submitted a marketing authorization application for pemigatinib to ANVISA, the Brazilian health regulatory agency, under the rare diseases approval pathway, for the treatment of adults with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor recepto
